LDS/Medical Tests/Nordoxepin, Urine

Nordoxepin, Urine

Nordoxepin (N-desmethyldoxepin) is a member of the class of drugs known as antidepressants, and is the major metabolite of doxepin. The use of tricyclic antidepressants (TCAs) are one of the primary ways to treat clinical depression. Nordoxepin is one of the first generation of antidepressants.

Nordoxepin, which is the major metabolite of doxepin, has similar biological activity as doxepin. Like the parent drug, the half-life of nordoxepin is between 9-25 hours.

The effects associated with nordoxepin abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay type test indicates only the presence of TCAs and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.
Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy).

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Specimens should be spun and the serum separated and refrigerated.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Antidepressant DEA Drug Fact Sheet L
  • evine B (ed). Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press. Chapter 14, Therapeutic Drugs II: Antidepressants, pp. 403-420; 2013.
  • Balant-Gorgia A.E., Balant LP. Therapeutic drug monitoring of antidepressants. Clin Thera, 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.